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Abstract Circulating cell-free DNA (cfDNA) is becoming an
important clinical analyte for prenatal testing, cancer diagno-
sis and cancer monitoring. The extraction stage is critical in
ensuring clinical sensitivity of analytical methods measuring
minority nucleic acid fractions, such as foetal-derived se-
quences in predominantly maternal cfDNA. Consequently,
quality controls are required for measurement of extraction
efficiency, fragment size bias and yield for validation of
cfDNA methods. We evaluated the utility of an external
DNA spike for monitoring these parameters in a study com-
paring three specific cfDNA extraction methods [QIAamp®
circulating nucleic acid (CNA) kit, NucleoSpin® Plasma XS
(NS) kit and FitAmp™ plasma/serumDNA isolation (FA) kit]
with the commonly used QIAamp DNA blood mini (DBM)
kit. We found that the extraction efficiencies of the kits ranked
in the order CNA kit > DBM kit > NS kit > FA kit, and the
CNA and NS kits gave a better representation of smaller DNA
fragments in the extract than the DBM kit. We investigated
means of improved reporting of cfDNA yield by comparing
quantitative PCR measurements of seven different reference
gene assays in plasma samples and validating these with
digital PCR. We noted that the cfDNA quantities based on
measurement of some target genes (e.g. TERT) were, on
average, more than twofold higher than those of other assays
(e.g. ERV3). We conclude that analysis and averaging of
multiple reference genes using a GeNorm approach gives a
more reliable estimate of total cfDNA quantity.
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Clinical/biomedical analysis . Diagnostics . Liquid
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Introduction
The discovery of cell-free DNA (cfDNA) in blood has pro-
vided an accessible source of genetic material from foetal
tissue [1], solid tumours [2, 3] or solid organ transplants [4].
Owing to the relative ease of access and the minimally inva-
sive nature of the sampling, cfDNA could be used to simplify
the longitudinal monitoring of disease progression or response
to treatment in cancer patients [5], where the term ‘liquid
biopsy’ has emerged to describe blood-based monitoring of
tumour genetics [6]. Analysis of cfDNA also provides a safer
alternative to amniocentesis or chorionic villus sampling for
prenatal diagnostics [7], or to organ biopsy for the detection of
transplant rejection [8]. Currently, measuring somatic muta-
tions, such as those observed in the Kirsten rat sarcoma viral
oncogene homologue gene (KRAS) [9], and copy number
variations, such as human epidermal growth factor receptor
2 (ERBB2, formerly known as HER2) amplification in breast
cancer [10] or foetal aneuploidy [11] in cfDNA, show consid-
erable clinical potential.
One of the main hindrances in using cfDNA as a robust
analyte is a lack of standardisation and appropriate controls in
this field as highlighted by a number of comprehensive reports
[6, 12–14]. These reviews attribute a lack of comparability
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between results to differences in sample processing methods
and storage conditions, and in techniques for both the extrac-
tion and quantification. Recently, progress has been made in
better definition of factors influencing preanalytical sample
processing and storage [15–17], but variability between ex-
traction methods and quantification approaches still presents
major potential sources of experimental error [18]. In our
study, we therefore focussed on the latter two aspects of
cfDNA analysis.
Circulating cfDNA is a challenging analyte for extraction
owing to its low concentration in plasma in normal individuals
(in the region of 1.8–44 ng/mL), although this can be in-
creased greatly in diseased or pregnant individuals [12]. Many
laboratories have evaluated and compared a number of differ-
ent extraction methods for the isolation of cfDNA from plas-
ma and have demonstrated that the extraction can differ con-
siderably in terms of efficiency depending on the method
[18–26]. Historically, many of the extraction methods used
in cfDNA studies, such as the QIAamp® DNA blood mini
(DBM) kit and the QIAamp DSP virus kit (both from
QIAGEN), were developed initially to extract high-integrity
genomic DNA from blood cells or virions, and not for highly
fragmented cfDNA [20, 25, 27, 28]. This could be responsible
for the noted inefficiency in some extraction methods pub-
lished. Although cfDNA is fragmented by nature and is pres-
ent in normal individuals, tumour-derived cfDNA can differ in
fragment size profile depending on the cellular process caus-
ing its release into the circulation [29, 30]. Furthermore, fetal-
derived cfDNA is often more fragmented than maternal
cfDNA, requiring separation approaches in order to improve
recovery of the fetal-derived fraction [31].
In addition to characterisation of extraction recovery, quan-
tification of the total amount of cfDNA is important in order to
define what fraction of the total is composed of the tumour- or
fetal-derived DNA. This fraction is required in non-invasive
prenatal diagnosis for the calculation of the relative chromo-
some dosage for assessment of fetal aneuploidies [32] or
relative mutation dosage approaches for single-gene disorders
such as sickle cell anaemia [33], as well as tumour diagnostics
for monitoring of cancer-associated copy number variations
[10]. The low concentration of cfDNA extracts makes quan-
tification of yield using methods such as UV spectroscopy or
fluorescence spectroscopy problematic [34]. Assays based on
quantitative PCR (qPCR) are often used for measurements of
cfDNA [12]. However, qPCR also has increased variability at
lower copy numbers [35], which may lead to further impreci-
sion and bias being introduced at the quantification stage.
The emergence of kits onto the market which are specifi-
cally developed for cfDNA isolation may aid in the robustness
and reproducibility of cfDNA extractions. These kits include,
but are not restricted to, the QIAamp circulating nucleic acid
(CNA) kit (QIAGEN), the NucleoSpin® Plasma XS (NS) kit
(Macherey-Nagel) and the FitAmp™ plasma/serum DNA
isolation (FA) kit (Epigentek). We present a comparison study
of three specific cfDNA extraction methods with the
established DBM kit. To monitor the extraction efficiency,
linearity of the extraction yield, presence of co-purified inhib-
itors and bias associated with fragment size, we developed an
in-house artificial spike-in material containing small (approx-
imately 100 bp), medium (approximately 500 bp) and large
(approximately 1,500 bp) fragment sizes. Finally, we investi-
gate how reliable the measurement of endogenous genes is for
quantification of total cfDNA in terms of bias and precision by
comparing measurements of seven genomic loci in 17 indi-
vidual plasma samples by qPCR and digital PCR (dPCR).
Materials and methods
Fragmentation of ADH plasmid
The pSP64 poly(A) plasmid containing the Arabidopsis
thaliana alcohol dehydrogenase gene (ADH) fragment
(GenBank ID M12196) was linearised with BglI as described
previously [36]. The 4.5-kb linearised plasmid was
fragmented in a double digest containing AlwNI, BsrDI and
bovine serum albumin to give six fragments of various sizes
(67, 115, 461, 530, 1,448, and 1,889 bp). Complete
linearisation and fragmentation was confirmed using a 2100
bioanalyzer and DNA 7500 series II kit (Agilent, South
Queensferry, UK) according to the manufacturer’s instruc-
tions (Fig. S1).
Human plasma samples
Plasma samples from 17 individual donors (20 mL EDTA-K2-
treated plasma per donor) were purchased from SeraLab and
stored on arrival at −80 °C. Female donors, aged 50–59 years
(median donor age of 53.1 years), were from Caucasian, black
or Hispanic backgrounds (Table S1). Samples were thawed
prior to pooling or DNA extraction, and residual cellular
debris was removed using centrifugation at 5,000 rpm for
3 min as previously described [37]. Two pools of plasma
samples were prepared: plasma pools A (i) and A (ii) were
prepared by mixing 8 mL from each donor sample numbered
1–5 (n=2), and plasma pool B was prepared by mixing 11 mL
from each donor sample numbered 6–17 (n=1) (Table S1).
Sample pools were homogenised by mixing them on a
SpiraMixer at 4 °C for 30 min. The fragmented ADH plasmid
was added to a 15-mL subaliquot of plasma pool A (i) as an
extraction control at 106 copies per millilitre of plasma [des-
ignated as “plasma pool A (i) + ADH”], following which
further homogenisation of the plasma subpool was performed
by rotation on a SpiraMixer at 4 °C for 30 min. All plasma
pools were stored in aliquots [plasma pools A (i) and A (ii),
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1.1 mL (all aliquots); plasma pool B, 1×35 mL, 2×45 mL] at
−80 °C.
DNA extraction
Four DNA extraction kits were used for comparison: QIAamp
CNA kit (QIAGEN), QIAamp DBM kit (QIAGEN), NS kit
(Macherey-Nagel) and FA kit (Epigentek). Replicate extrac-
tions were performed with plasma pool A (i) (n=6) and
plasma pool A (i) + ADH [n=4; n=3 (DBM kit)]. One
millilitre of plasma was processed per extraction with the
CNA and DBM kits and 0.5 mL plasma was processed with
the NS and FA kits in line with the manufacturers’ recom-
mended input ranges. For the CNA kit, samples were proc-
essed according to the manufacturer’s protocol for 1-mL input
volume with an elution volume of 50 μL. For the DBM kit,
cfDNA was extracted from plasma as described by
Fleischhacker et al. [18] in spin-column format with an elution
volume of 50 μL. For the NS kit, the high-sensitivity protocol
was followed, including the optional proteinase digestion
stage, with an elution volume of 20 μL. For the FA kit, the
standard protocol was followed with an elution volume of
18 μL. Extracts were made up to final volumes of 200 μL
(CNA and DBM kits) and 100 μL (NS and FA kits) with
nuclease-free water, giving a final equivalent concentration of
5 μL plasma per microlitre of extract for all samples.
To assess inhibition of qPCR by components of cfDNA
extracts, the two kits with the possibility of producing the
maximum concentrations of cfDNA in the eluate were select-
ed: the CNA and NS kits. Extractions were performed with
plasma pool A (ii). For the CNA kit, three extractions were
performed with 5 mL plasma and an elution volume of 20 μL,
followed by pooling (final concentration equivalent to
1,250 μL plasma per microlitre of extract). For the NS kit,
six replicate extractions were performed with 0.6 mL plasma
and an elution volume of 10 μL, followed by pooling (final
concentration equivalent to 300 μL plasma per microlitre of
extract). Subsequently, dilutions were prepared in nuclease-
free water.
For investigation of the linearity of extraction efficiency,
plasma input volumes of 1, 2, 3 and 5 mL (n=3) from plasma
pool B were processed with the CNA kit, which has the largest
range of possible plasma input volumes of the kits tested, and
were eluted in 50 μL elution buffer. Three independent sets of
extractions were performed. Extracts were analysed undiluted
by qPCR (equivalent to 20μL plasma per microlitre of extract).
Two sets of DNA extractions from 17 individual donor
plasma samples were performed with 1 mL plasma using the
CNA kit with elution volumes of 50 μL (Fig. 5) and 20 μL
(Figs. 6, 7). The smaller final volume was used to increase the
cfDNA concentrations in extracts for dPCR analysis. For
qPCR analysis, extracts were diluted to the equivalent 25 μL
plasma per microlitre of extract.
Real-time qPCR
Real-time qPCR assays for human genomic targets telomerase
reverse transcriptase (TERT) and ribonuclease P RNA com-
ponent H1 (RPPH1) were designed using Primer Express®
(Applied Biosystems). Additional assays for human genomic
targets ALUJ [38], endogenous retrovirus group 3 (ERV3)
[28], glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
[39] and N-acetylglucosamine kinase (NAGK) [40] were
based on previous publications. A commercial assay
ValidPrime™(VP) designed to a non-transcribed genomic
locus present at one copy per haploid normal genome was
obtained from TATAA Biocenter (Göteborg, Sweden). Se-
quences present in the ADH plasmid insert sequence were
quantified using Adhβ and Adhδ assays [36] or an assay for
the 115-bp fragment of the plasmid backbone ‘ADH-115 bp’
(Fig. S1) designed using Primer Express. Detailed information
relating to PCR assays is provided in Table S2. All qPCR
experiments were performed in accordance with the MIQE
guidelines [35] (Table S3, part A).
Triplicate qPCR assays were performed for each point of
the standard curve, and test samples were assessed in single
reactions, unless stated otherwise in the figure legends. For
the endogenous targets and ALUJ assays, a seven-point
fivefold dilution series (from approximately 3,042 to ap-
proximately 0.2 haploid genome copies per reaction) of
female human genomic DNA (Promega) prepared in yeast
transfer RNA (50 ng/μL) (Sigma) diluent was used for
generation of the standard curve. ALU is a repetitive se-
quence found at high copy number in the genome [41, 42],
and so the standard curve was generated as genome equiv-
alents rather than copies as for the other genomic targets.
To assess recovery of the exogenous spike-in from cfDNA
extractions, a four-point tenfold dilution series (from 50,000
to 50 copies per reaction) of the fragmented ADH plasmid
(diluent, nuclease-free water) was used to measure the
number of copies of each ADH plasmid fragment. ADH-
115 bp, Adhβ and Adhδ assays were used to measure the
recovery of the 115-, 461- and 1,448-bp ADH plasmid
fragments, respectively. Assessment of qPCR inhibition of
the Adhβ assay by cfDNA extracts using the CNA, NS and
FA kits (without addition of the ADH plasmid before
extraction) was performed using the same dilution series
of ADH plasmid in the presence of 5 μL cfDNA extract
and qPCR efficiency determined on the basis of the slope
of the linear regression analysis of quantification cycle (Cq)
versus concentration (copies per reaction).
To further assess inhibition of qPCR by components of
cfDNA extracts prepared using the CNA and NS kits,
fragmented ADH plasmid (500 copies) was added to each
Adhβ assay in addition to 5 μL of concentrated or diluted
cfDNA extract, and Cq values were compared with the control
condition (absence of cfDNA extract).
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For all experiments unless otherwise stated, 20-μL reac-
tions containing 5 μL sample were performed using universal
master mix or gene expression master mix (Table S2) and the
7900HT fast real-time PCR system (all Life Technologies).
For all experiments, no-template controls were performed
with the addition of diluent without cfDNA extract or ADH
plasmid. Results for the no-template controls are given in
Table S4. The thermal cycling conditions were as follows:
50 °C for 2 min, 95 °C for 10 min, 40 cycles of 95 °C for 15 s
then 60 °C for 60 s. For the ALUJ assays, 20-μL reactions
containing 5 μL sample were performed using Power SYBR®
Green master mix (Life Technologies) using the same cycling
conditions as mentioned above with the addition of a melting
step at the end to check the dissociation curve for the presence
of primer-dimers and non-specific products: 95 °C for 15 s,
60 °C for 15 s followed by an increase in temperature to 95 °C
at a ramp rate of 2 %. SDS version 2.4 (ABI) was used to
calculate Cq, which is defined as the number of cycles at
which the fluorescence signal is significantly above the
threshold. Data were exported for further analysis inMicrosoft
Excel® 2003/2007.
Droplet dPCR
The details and sequences of the dPCR assays were identical
to those used in real-time qPCR experiments (Table S2).
Digital PCR (dPCR) experiments using the QX100™Droplet
Digital™ PCR system (Bio-Rad) were performed in accor-
dance with the dMIQE guidelines [43] (Table S3, part B).
Final-volume reactions of 20 μL containing ddPCR™
supermix (Bio-Rad) and 3.5 μL sample were established prior
to droplet formation using the QX100 droplet generator ac-
cording to the manufacturer’s instructions. Briefly, each
20-μL reaction mixture was pipetted into the sample well of
a DG8 cartridge with 70 μL generator oil pipetted into the oil
well. Droplets were generated by the QX100 droplet genera-
tor, and 40 μL of droplets was transferred, using a multichan-
nel pipette, into a 96-well plate. Each plate was sealed with
foil using a PX1™ PCR plate sealer, and PCR was performed
using a C1000 Touch™ thermal cycler. The thermal cycling
conditions were as follows: 95 °C for 10 min, 40 cycles of
94 °C for 30 s then 60 °C for 30 s followed by 98 °C for
10 min and cooling to 4 °C. Droplets were analysed using the
QX100 droplet reader according to the manufacturer’s instruc-
tions. Data were analysed using QuantaSoft™ version 1.3.2.0
to count the number of positive droplets (m) and the total
number of accepted droplets (n). The mean number of copies
per droplet (λ) was estimated using the relationship λ=−ln(1
−m/n), which assumes a Poisson distribution for the number
of copies in each droplet (Table S5) [43, 44]. Data were
exported for further analysis into Microsoft Excel
2003/2007. The number of template copies per microlitre
was calculated using the published manufacturer’s volume
of 0.91 nL per droplet, and confidence intervals were calcu-
lated as described previously [45]. For all experiments, no-
template controls were established in parallel with diluent
added without cfDNA extract (Table S5).
Data analysis
Data were analysed in Microsoft Excel 2003/2007 and
Graphpad Prism® version 5.04. All data were converted to the
number of copies per millilitre of plasma, where one copy is
either for the single gene measured or as a single human haploid
genome that is calculated as 3.3 pg. Reference gene stability of
seven reference genes in the group of 17 donors (Fig. 5) was
analysed using the GeNorm algorithm in GenEx Enterprise
version 5.3.6 (MultiD Analyses, Göteborg, Sweden) [46].
One- and two-way analysis of variance (ANOVA) tests
(Figs. 1, 2, 3, 4b), regression analysis (Fig. 4a) and Pearson
correlation analysis (Table S5) were performed using
Graphpad Prism version 5.04. Analysis of reference gene
copy numbers in cfDNA extracts (Figs. 5, 6, 7) was performed
with log10-transformed values in R version 3.0.1 [47] using
linear models, with the reference gene and the donor as fixed
variables. Two-way ANOVAwas performed, and differences
between reference genes were compared using Tukey’s honest
significant difference test (see the electronic supplementary
material). Further information is given in the electronic sup-
plementary material.
An average cfDNA quantity for each donor based on
TERT, RPPH1 and ERV3 copy numbers (GeNorm approach)
was calculated as the arithmetic mean of log10-transformed
values. We calculated 95 % confidence intervals of the




















Fig. 1 Assessment of cell-free DNA (cfDNA) yield using four extraction
methods. The mean yield ± one standard deviation from replicate extrac-
tions using plasma pool A (i) (with or without ADH) performed with the
QIAamp circulating nucleic acid (CNA), NucleoSpin PlasmaXS (NS) and
FitAmp plasma/serum DNA isolation (FA) kits (n=10) and the QIAamp
DNA blood mini (DBM) kit (n=9) is displayed relative to the mean yield
of the DBM kit. The yield of cfDNAwas quantified by quantitative PCR
(qPCR) assays to TERT and ALUJ
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associated with the reference gene and qPCR replicate by one-
way ANOVA (Graphpad Prism) (see the electronic supple-
mentary material). The mean square between-group (MSr)





where b is the number of groups (reference genes) and n is the
number of replicate qPCR measurements. The 95 % confi-
dence interval was calculated by multiplying the standard
error σ by the coverage factor k associated with two degrees
of freedom (three groups) for α=0.05 (k=4.3). The log-
transformed values were transformed to linear scale (Fig. 7).
Results
We compared three kits specifically developed for the extrac-
tion of cfDNA from body fluids (CNA, NS and FA kits) with
the DBM kit (which has been used widely for this application
[18]) using plasma pool A (i). The yields of cfDNA in terms of
genome equivalents per millilitre of plasma for each of the
four methods were assessed by qPCR measurement of two
reference assays, one for the single-copy gene TERT, and the
other for the genomic repetitive element (ALUJ). The values
are expressed as percent yield compared with the mean yield
of the DBM kit (Fig. 1). The results were consistent between
both reference assays and suggested that the yield of cfDNA
per millilitre of plasma was between 2.2-fold and 2.5-fold
higher with the CNA kit than with the DBM kit, whereas the
NS extracts contained less than half the cfDNA yield of the
DBM extracts. Extracts obtained using the FA kit contained
very low levels of cfDNA, which were not detectable by the
TERT assay and were estimated to contain approximately one
genome copy per millilitre of plasma by the ALUJ assay
(Fig. 1).
To investigate further extraction kit DNA recovery and
DNA fragment bias, a spike-in containing the digested ADH
plasmid was added to a subpool of plasma prior to isolation of
cfDNA [plasma pool A (i) + ADH]. The recovery of the 115-,
461- and 1,448-bp fragments was measured after extraction
using three qPCR assays detecting sequences present in these
fragments (ADH-115 bp, Adhβ and Adhδ, respectively) in
order to evaluate the fragment size profile of the extraction
methods (Fig. 2).
In line with the results from the endogenous targets (Fig. 1),
the extraction efficiency of the CNA kit was the highest of the
four methods, with over 80 % recovery for all three fragment
sizes. Average approximately twofold and approximately 4.8-
fold lower extraction efficiencies were noted for the DBM and
NS methods, respectively (Fig. 2). For the FA kit, recovery of
the exogenous DNAwas also lower (less than 0.1 % recovery
of all three ADH fragments). The NS kit demonstrated an even
profile in terms of recovery of both smaller and larger DNA
fragments. Although the CNA kit recovered a high percentage
(83 %) of the smallest plasmid fragment (115 bp), the yield of
this was not as high as that of the 461-bp fragment (99 %)
(p<0.05). The DBM kit demonstrated the highest recovery of
the largest, 1,448-bp fragment (58 %), compared with 37 %
recovery of the 461-bp fragment (p<0.05) and 21 % recovery
of the 115-bp fragment (p<0.0001). The repeatability associ-
ated with replicate extractions for each kit was consistent
between the results of endogenous and plasmid targets, with
the CNA and DBM kits demonstrating a mean repeatability
percent coefficient of variation (CV) of 10 % for all assays,
compared with 49 % for the NS kit (Table S6) (data not
presented for the FA kit owing to the low yield).
One advantage of the CNA and NS kits is the ability to
concentrate cfDNA, through the use of either large collection
tubes for processing up to 5 mL plasma (CNA kit) or a
specially designed purification column allowing elution vol-
umes as low as 5 μL (NS kit). These more concentrated
extracts are ideally suited for new technologies such as dPCR,
which typically use smaller volumes of samples per assay
compared with qPCR [45, 48]. However, these highly con-
centrated extracts may also contain higher concentrations of
PCR inhibitors present in the extraction matrix (such as blood
tube preservatives [49]). To investigate this, replicate extrac-
tions were performed using plasma pool A (ii) with the max-
imum plasma input volume of the two kits (5 mL for the CNA
kit and 0.6 mL for the NS kit) together with the minimum
elution volumes (20 and 10 μL, respectively), followed by































Fig. 2 Assessment of extraction efficiency and fragment size bias of four
extraction methods using an exogenous spike-in. Extraction efficiencies
of the CNA, NS, FA and DBM kits are expressed as a percentage of input
(106 copies per millilitre of plasma) ± one standard deviation (n=3
extractions for the DBM kit, n=4 extractions for the other methods) for
115-, 461- and 1,448-bp fragments of the ADH plasmid spike-in. Signif-
icant differences between the yields of the ADH plasmid fragments are
indicated: one asterisk, p<0.05; four asterisks, p<0.0001
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the concentrated extracts inhibited qPCR (Fig. 3). Inhibitory
substances in the extracts were assayed by spiking the qPCR
with ADH plasmid and measuring Cq using the Adhβ assay.
The assay was performed in two formats with either a hydro-
lysis probe (Figs. 3a, b, S2) or using intercalating dye chem-
istry (Fig. 3c, d). An increase in Cq versus the control reaction
was judged to indicate inhibition of the qPCR. Reactions
contained 4 μL sample with concentrations equivalent to
6.25, 15, 30 and 60 μL plasma per microlitre for the CNA
and NS kits, and additionally 125 and 250 μL plasma per
microlitre in the case of the CNA kit. The TaqMan-based
Adhβ assay did not show any evidence of inhibition with
extracts from either the CNA (Fig. 3a) or the NS (Fig. 3b)
extracts. The CNA kit extracts did not inhibit the SYBR-based
Adhβ assay up to concentrations of 125 μL plasma per
microlitre; however, at the maximum concentration of
250 μL plasma per microlitre of extract (equivalent to 1 mL
plasma extract per qPCR), a mean shift of approximately 2.0
Cq units was observed (Fig. 3c). The NS kit extracts did not
inhibit the SYBR-based Adhβ assay (Fig. 3d).
On the basis of the results of the assessments of yield,
fragment size distribution and presence of inhibitors (Figs. 1,
2, 3), the CNA kit was chosen as the most suitable extraction
method for high-sensitivity cfDNA analysis. We further eval-
uated the performance of this kit in terms of linearity of yield
andwithin-laboratory reproducibility (intermediate precision).
Plasma can be processed using this kit with input volumes
between 1 and 5 mL, and so we tested whether the cfDNA
yield was proportional to the plasma input volume by
performing independent extractions of plasma pool B with
1, 2, 3 or 5 mL plasma (n=3 replicates per experiment) on
three different days and with elution in a fixed volume. The
yield of cfDNA was assessed using the TERT assay (Fig. 4).
Log-transformed cfDNA yields in the CNA extracts were
normally distributed (analysis not shown) andwere linear with
respect to input volume up to an input volume of 3 mL plasma
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Fig. 3 Assessment of qPCR inhibition by cfDNA extracts using two
different extraction methods. Fragmented ADH plasmid (500 copies per
reaction) was measured using the Adhβ assay (qPCR, n=3) in both
hydrolysis probe (a, b) and intercalating dye (c, d) assay formats in the
presence of increasing concentrations of cfDNA extract produced using
the CNA (a, c) and NS (b, d) kits and compared with control conditions
(given a nominal concentration of 1 μL plasma per microlitre of extract
owing to plotting on a log scale). Individual data points represent replicate
qPCR assays. An increase in Cq indicates inhibition of qPCR versus the
control condition. Three asterisks, p<0.001
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per extraction (R2=0.90) (Fig. 4a). Yield expressed as per
millilitre of plasma was found to be significantly different
between the four different input volumes on the basis of
ANOVA (p=0. 015). This is consistent with the regression
analysis (Fig. 4a), and suggests a slight reduction in extraction
efficiency at 5 mL plasma per extraction (Fig. 4b). However,
post hoc analysis did not indicate significant differences be-
tween specific volumes (data not shown). No significant dif-
ferences in yield per millilitre of plasma were found between
the three independent extractions (Fig. 4b). The within-
laboratory reproducibility was calculated as a CV of 17 %,
composed predominantly of within-day variability (16 %),
which was consistent with repeatability data using 1 mL plas-
ma per extraction (Fig. 1, Table S6).
Having assessed different technical aspects of the perfor-
mance of cfDNA extractionmethods, we investigated controls












































Fig. 4 Linearity and within-laboratory reproducibility of cfDNA extrac-
tion using a single method. Three independent extraction experiments
performed on different days using the CNA kit were performed with 1, 2,
3 and 5mL plasma pool B (n=3 replicates per day). a The yield of cfDNA
(copies per extraction) is compared with the volume of plasma (mL)
processed per extraction using the CNA kit (n=9 per volume). Data
points correspond to individual extracts. b The within-laboratory repro-
ducibility of extract yield per millilitre of plasma is compared for different
input volumes and three independent experiments. Mean values ± one

























ALUJFig. 5 Comparison of cfDNA
copy number of seven different
reference genes in 17 donor
samples measured by qPCR
assays. The results for each
reference gene are displayed with















Fig. 6 Comparison of fold differences between reference genes mea-
sured by qPCR and droplet digital PCR (dPCR). The ratios of TERT/
ERV3 and RPPH1/ERV3 genomic copy numbers in extracts from 17
plasma samples are compared for qPCR-based and droplet-dPCR-based
measurements. Box and whisker plots depict the median value (line),
interquartile range (box) and upper and lower limits (whiskers) based on
Tukey’s honest significant difference test. Outlier values are indicated as
single points
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assay normalisation to total cfDNA. The total cfDNA isolated
from plasma samples from 17 individual donors was quanti-
fied using seven different reference assays. In addition to an
assay for TERT, a number of assays for single-copy genomic
targets commonly used for cfDNA measurements (RPPH1,
GAPDH, NAGK and ERV3) were also used, as well as a
commercial assay VP, designed for an undisclosed single-
copy locus. These results were compared with the genome
equivalent estimate based on measurement of the ALUJ repeat
element.
Analysis of all seven assays demonstrated that most of the
samples contained a mean of fewer than 2,500 copies per
millilitre of cfDNA (equivalent to 8 ng/mL or less). However,
samples from two donors (donors 5 and 9) contained larger
amounts of cfDNA [mean (range) 24.6 (12.4–36.6) ng/mL
and 12.5 (7.2–17.5) ng/mL, respectively] (Fig. S3). The seven
assays showed strong correlation based on the donor, with
correlation coefficients (r) between 0.86 and 0.97 (Table S7).
The reference genes were also analysed in terms of stability
according to the GeNorm algorithm, which is commonly
applied to reference gene normalisation of messenger RNA
measurements [46] (Table S8). Good stability (M) values were
calculated for all seven assays (M<0.4), suggesting all refer-
ence genes could be suitable markers of cfDNA quantity.
However, absolute differences between the genomic copies
were observed (Fig. 5). On the basis of linear modelling of
results from all donors, copy number measurements were
ranked in the following order: TERT~ALUJ > NAGK ~
GAPDH > RPHH1 > ERV3 ~ VP. TERT- or ALUJ-based copy
number measurements were, on average, between 138 and
173 % greater than those based on ERV3 or VP, whereas
RPPH1 copy numbers were approximately 60 % higher than
those of ERV3 (see the electronic supplementary material).
We speculated as to whether the discordance between
individual reference gene measurements could be attributable
to artefacts of the standard calibration curve. Selected samples
were therefore analysed by droplet dPCR, which does not
require a standard curve for absolute quantification
(Fig. S4). Measurements were performed with three assays
representative of high (TERT), medium (RPPH1) and low
(ERV3) copy numbers. There was good agreement between
the qPCR and droplet dPCR measurements of copy numbers
(Fig. S5). When the results of the three different assays were
compared by linear modelling, the same rank order of copies
per millilitre of extract was observed as for qPCR, although
the fold differences were not as large. For example, TERT and
RPHH1 copy number measurements were on average 50 %
and 30 % higher than those of ERV3 (vs 165 % and 60 %,
respectively, by qPCR) (Fig. 6; see also the electronic supple-
mentary material).
The observed differences between qPCR and droplet



















ALUJ TERT RPPH1 ERV-3
Fig. 7 Comparison of a multiple
reference gene approach for
plasma cfDNA quantification
with single gene measurements.
The 95 % confidence interval
(grey area) associated with a
normalised geometric average
cfDNA quantity calculated on the
basis of three reference genes
(TERT, RPPH1, ERV3) and three
independent qPCR experiments is
compared with mean estimates
for each of the above-mentioned
reference genes and ALUJ for
each donor
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quantification biases in the total cfDNA could be introduced.
Calculation of an average value based on measurement of
multiple reference assays was therefore investigated as a
means of improving the accuracy of the cfDNA load quanti-
fication, by comparing the cfDNA load estimated by single
reference genemeasurements (TERT, RPHH1 and ERV3) with
the mean of all three targets. Precision was calculated by
performing three independent qPCR experiments with 12 of
the 17 samples previously analysed (Fig. 5). Single copy loci
reference gene measurements were also compared with the
multicopy genomic repeat ALUJ. For most of the samples, the
apparent copy number abundances observed in the initial
analysis of individual donor samples (Fig. 5) were also ob-
served in the repeated analysis, in that ALUJ and TERT
genomic copies exceeded those of RPHH1, which in turn
were higher than those measured for ERV3 (Fig. 7; see also
the electronic supplementary material). The arithmetic mean
of the log-transformed copy number measurements for the
three single-copy loci was calculated (note that this is equiv-
alent to the geometric mean using non-log-transformed copy
numbers), along with the 95 % confidence interval, based on
the variation between the three loci and the precision of
independently replicated measurements (see “Materials and
methods”). The range covered by the upper and lower limits
of the expanded uncertainty occupied a central region (Fig. 7,
shaded area), approximately between the higher TERT- and
ALUJ-based estimates and the lower ERV3 measurements.
This suggests that the mean copy number based on multiple
reference genes gave a good approximation of the possible
range of cfDNA genomic copies present.
Discussion
The potential of cfDNA in plasma as a source of minimally
invasive material for molecular diagnostics is beginning to be
realised. Several reports highlighting the lack of
standardisation in this field [12, 13, 50] and comparison of
different extraction methods have begun to elucidate the im-
pact of different methods used on the quantification of the
resulting cfDNA [18–24, 26]. In this study we have investi-
gated cfDNA standardisation by applying different strategies
to the quantification of cfDNA, including an in-house artificial
spike-in control material along with targeting of endogenous
(reference) genes to measure total cfDNA present in a sample.
Although it is generally accepted that most of the variation
observed between different individuals will be biological,
there are many technical considerations that could cause a
wide range of measurement discrepancies. Our data have
confirmed that one of the principal causes of technical vari-
ability comes from the different isolation methods used, where
the yield and efficiencies of extracted cfDNA from the same
plasma samples can differ by orders of magnitude (Figs. 1, 2).
By comparing three kits designed especially for the isolation
of cfDNA from plasma with the commonly used DBM ex-
traction kit, we demonstrated that the CNA kit produced a
higher yield than the other kits.
The higher yields of the CNA kit compared with the DBM
kit is consistent with a recent report [19], but the DBM kit was
found to be more comparable to the CNA kit by Page et al.
[23], although this may be due to the different adaptations of
the DBM kit for cfDNA extraction in use as the report also
showed reduced cfDNAyields using the FA kit. However, by
adding a plasmid spike-in control material to plasma prior to
extraction, our study was able to assign a measure of extrac-
tion efficiency, further stratified by fragment size, to method
performance. For the CNA kit, this suggested that nearly all
cfDNA(83–100 %) was recovered. The repeatability of the
extraction stage was also shown to differ between methods,
with the CNA and DBM kits having a CVof less than 15 %,
whereas the repeatability of NS kit was more variable
(approximately 50 %).
Further technical factors whereby extraction may influence
the quality of cfDNA analysis were investigated in our study.
Kits developed specifically for cfDNA analysis offer the
possibility of large input and/or small elution volumes. This
may compound problems associatedwith amplification of low
copy number templates by increasing the carryover of poten-
tial inhibitors into downstream analysis methods such as
qPCR. The data here demonstrated that although the two kits
tested (CNA and NS kits) were capable of producing highly
concentrated cfDNA extracts (up to the equivalent of 250 μL
plasma per microlitre of eluate and 100 μL plasma per
microlitre of eluate for the CNA and NS kits, respectively),
alternative qPCR detection methods were affected differently
by inhibitors, with the intercalating dye method less tolerant of
the highest extract concentration compared with hydrolysis
probe chemistry (Fig. 3). This is in agreement with our earlier
observations [51].
Cell-free (cfDNA) extractions are commonly performed on
1 mL of plasma [18, 23]. By checking the extraction efficien-
cy with larger plasma input volumes, we have shown that total
cfDNA yield increases with increased input volumes proc-
essed using the CNA kit (Fig. 4a), at least until the maximum
input volume of 5 mL plasma, where a small reduction in
extraction efficiency may occur (Fig. 4). It is proposed that
this may be due to plasma matrix components reducing flow
through the column and impacting absorption of nucleic acids
[24]. However, the advantage of sample concentration with
larger input volumes outweighs any slight reduction in effi-
ciency, especially for minority detection, where larger input
volumes offer the possibility of improved sensitivity of de-
tecting the minority variant [24].
It is quoted frequently that the expected amount of cfDNA
from plasma in a normal human is of the order of 1,000
genome equivalents per millilitre of blood [52]. However,
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not only does this value vary considerably in the literature [12,
34], but the unit used to report the value also varies (absorp-
tion units, nangrams per millilitre of plasma, etc.) and the
method used to convert one unit to another (e.g. conversion
of nanograms per millilitre to genome equivalents per
millilitre) is based on certain assumptions, such as uniform
genome representation in a sample and 3.3 pg as the weight of
a human haploid genome. This conversion has relevance for
quantification of targets present as single copies per haploid
genome that are commonly used as reference genes for copy
number variation assays. Such normalisation is required for
detection of amplification or deletion in disease states, such as
ERBB2 amplification in breast cancer [10].
Likewise, the sensitivity of techniques to measure tumour-
derived somatic mutations is commonly defined as a percent-
age of the wild-type target. Consequently, it is useful to know
how many wild-type genome equivalents are present in a
cfDNA sample in order to decide whether an assay is capable
of measuring either the amplification of particular loci or a
mutation present at 0.1 % (i.e. one copy per 1,000 genome
equivalents). In these instances, the measurements of a single
locus may be compromised by low technical reproducibility
and biases due to its overrepresentation or underrepresentation
in the cfDNA. By comparing seven different assays for com-
monly used reference gene loci, this study has shown the
resulting estimate of total genome equivalents per millilitre
of plasma can vary by over twofold in magnitude within the
same normal female donor (Fig. 5). This clearly demonstrates
potential problems when targeting a single genomic region for
estimating the abundance of cfDNA.
The droplet dPCR validation of the qPCR reference assay
measurements led us to conclude that there could be both
technical and biological reasons for disparity in the copy
number estimates from the different reference loci observed
using qPCR measurements (Fig. 5). Although the same rank-
ing of copy number abundances was observed for the three
gene targets investigated using both approaches, the magni-
tude of the difference was greater using qPCR compared with
droplet dPCR measurements (Fig. 6). This suggests that there
may be artefacts of the standard-curve-based measurements
for qPCR leading to higher copy numbers being observed for
some reference genes compared with others. In this study, our
standard curves were based on good-quality genomic DNA as
surrogate material, for cfDNA is hard to obtain. As dPCR does
not need standard curves for quantification, this approach
removes this potential source of bias from the data.
The similarity in ranking between qPCR and droplet dPCR
measurements suggests that different loci are present at dif-
ferent proportions in the cell-free fraction from those present
in cellular genomic DNA. Of note is that loci that are more
telomeric in location (TERT and GAPDH) are more abundant
than those with a more centromeric position (ERV3 and
RPPH1), with NAGK, which is centrally located in the short
arm of chromosome 2, ranked in-between. ALUJ is ranked
level with TERT; this is consistent with the predominant
telomeric location of these repetitive sequences [53]. Two
recent studies using next-generation sequencing have demon-
strated that the entire fetal genome can be isolated from the
cfDNA in maternal plasma [54, 55]. This demonstrates that
although there may be little or no bias in the presence or
absence of certain genomic sequences, a single genomic locus
or element cannot necessarily meet the requirements to stan-
dardise quantitative measurement of the tumour- or fetal-
derived cfDNA fraction to the total cfDNA pool.
To generate a more robust method for standardised deter-
mination of the genomic content of cfDNA, this study applied
the widely accepted best practice principle for gene expression
analysis of multiple reference gene normalisation [46, 56]
(Fig. 7). The GeNorm factor, or multigene average value, is
the geometric mean of the copy number quantities for each of
the constituent reference gene assays [46]. This is mathemat-
ically equivalent to the arithmetic mean of log-transformed
quantities (as presented here). By applying the principle of
GeNorm normalisation to cfDNA analysis, we calculated an
average measurement that avoids a systematic overestimation
or underestimation of total cfDNA load.We also outlined how
the confidence interval of cfDNA loadmay be calculated from
the contributions from reference gene variability and assay
precision (based on independent qPCR measurements) and
demonstrated that this approach is consistent with any of the
single-gene estimates of cfDNA quantity (Fig. 7). Hindson
et al. [44] also applied the principle of multiple reference gene
averaging for quantification of total cfDNA for non-invasive
prenatal diagnosis using four genetic loci using droplet dPCR.
In this case, the contribution of each target to the overall
average was weighted according to assay precision.
Calculating the confidence interval or ‘measurement un-
certainty’ associated with total cfDNA load may help to
characterise the sample prior to multiple downstream analyses
(e.g. screening for several different biomarkers) and guide
clinical boundaries relating to the concentration, and measur-
able differences, of a specific biomarker. For example, the
mean and the confidence interval for total cfDNA load for
donor 1 (Fig. 7) were 1,400 copies per millilitre of plasma and
500–3,800 copies per millilitre of plasma, respectively. If a
mutant biomarker is present at 14 copies per millilitre, the
confidence interval associated with the total cfDNA load
would predict an abundance of the biomarker of between 0.4
and 2.7 % (mean 1 %). Figure 7 shows our estimate of the
confidence interval may be conservative, as we included refer-
ence genes with the largest difference in copy number ranking
(TERT and ERV3). Using three reference genes also means that
the result has two degrees of freedom, and the associated
confidence intervals are based on a Student’s t value of 4.3.
Inclusion of additional genomic loci in the reference gene panel
could improve the confidence of the estimate of cfDNA load,
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and this may be necessary if more precise measurements are
required (e.g. when measuring smaller fold changes).
We therefore recommend that, in the same way as reference
messenger RNAs are selected on the basis of their stability for
gene of interest normalisation [57, 58], a panel of genomic
reference loci be screened in samples from the intended clinical
cohort in order to ensure that a representative cross-section of
the genome is measured in order to assign cfDNA load.
Conclusions
The potential of cfDNA as an analyte for tumour and prenatal
diagnostics as well as a prognostic indicator for transplant
rejection [59] and sepsis [60] is becoming increasingly appar-
ent. A number of different techniques are being applied to
circulating cfDNA analysis, from targeted approaches such as
dPCR [61, 62] and deep sequencing ofmutation hotspots [63],
to whole exome and whole genome sequencing [64, 65].
Accurate quantification of total cfDNAwill aid future clinical
implementation of such approaches through quality assurance
of technical performance (e.g. ensuring input quantity is suf-
ficient to achieve the required sequencing depth). For non-
invasive prenatal diagnosis of fetal aneuploidies, it is also
important to characterise the fraction of total cfDNA which
originates from the fetus [66].
In this study, we have investigated the efficiency of methods
for extraction of cfDNA from plasma and have demonstrated
how a spike-in containing fragment sizes relevant to cfDNA can
be used to assess recovery of differently sized DNA. We have
applied a strategy developed for standardisation of messenger
RNA to cfDNA load measurements using multiple reference
genes to minimise biases due to assay or genome location. This
report is timely in raising awareness of the need, and establishing
a benchmark, for standardisation of the extraction and quantifi-
cation of cfDNA in these exciting fields ofmolecular diagnostics.
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